Skip To Main Content
Iomedico Ag on Muck Rack

Iomedico Ag

As seen in: Annals of Oncology, TrialBulletin.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Iomedico

Contact Iomedico, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma...

|
By Iomedico Ag
| TrialBulletin.com
Overview The non-interventional study SEATTLE aims to answer open scientific questions regarding QoL and tolerability/safety and AE management of selinexor as well as effectiveness and dosing in clinical routine. Thus, SEATTLE will provide real-world evidence complementary to pivotal studies.
Open in Who Shared Issue with article?

Efficacy and safety of nab-paclitaxel in patients with metastatic breast cancer: final results of the non-interventional study NABUCCO

|
By K. Potthoff, Iomedico Ag, A. Nusch, Krebszentrum Ratingen
| Annals of Oncology Verified
Background: One of the most effective chemotherapies for metastatic breast cancer (MBC) is nab-paclitaxel (nab-P) which is approved for the treatment of MBC after failure of 1st-line therapy and when anthracyclines are not indicated. Randomized clinical trials have shown high efficacy and acceptable toxicity. Real world data of nab-P in MBC, however, are still limited.
Open in Who Shared Issue with article?
See all 2 articles